Kura Oncology, Inc. (KURA) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 23, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the KURA SEC filings page.
Kura Oncology, Inc. (KURA) reported $77.2M in revenue over the twelve months to Jun 30, 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue is growing, but escalating research and overhead costs and a weakening balance sheet keep the business cash-consuming.
The key shift is that reported growth is not producing operating leverage: revenue increased25.2% in FY2025 while net profit margin worsened by90.1 percentage points . Cash conversion is unstable: operating cash flow shifted from$134.3M in FY2024 to-$64.1M in FY2025, showing that the prior year's positive free cash flow was not a stable earnings-to-cash pattern.
The balance sheet became more liability-funded: total liabilities rose
The expense base is larger than reported sales: R&D reached
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Kura Oncology, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Kura Oncology, Inc. held $667.2M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $64.1M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Kura Oncology, Inc. scores 95/100 among other emerging companies.
Kura Oncology, Inc. had 88M shares outstanding at the end of fiscal year 2025, against 81M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Kura Oncology, Inc. scores 53/100 among other emerging companies.
Kura Oncology, Inc. spent $251.1M on research and development in fiscal year 2025, which was 67.7% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Kura Oncology, Inc. scores 87/100 among other emerging companies.
Kura Oncology, Inc. reported revenue of $67.5M in fiscal year 2025, against $53.9M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Kura Oncology, Inc. scores 68/100 among other emerging companies.
Kura Oncology, Inc.'s operations used $64.1M of cash in fiscal year 2025, against $134.3M generated in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Kura Oncology, Inc. scores 74/100 among other emerging companies.
Kura Oncology, Inc.'s cash, cash equivalents and investments came to $667.2M at the end of fiscal year 2025, against $564.2M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Kura Oncology, Inc. scores 64/100 among other emerging companies.
Kura Oncology, Inc. scores -1.62, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $1.2B against total assets of $738.4M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Kura Oncology, Inc. passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), the one computable operating efficiency signal (asset turnover improving) passes.
Kura Oncology, Inc. reported a net loss of $278.7M while operations used $64.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Kura Oncology, Inc. reported an operating loss of $303.6M against $1.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Kura Oncology, Inc. generated $20.9M in revenue in Q2 2026. This represents an increase of 36.5% from the same quarter a year earlier. Against the prior quarter it is up 14.3%.
Kura Oncology, Inc.'s EBITDA was -$72.6M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Kura Oncology, Inc. reported a net loss of $68.3M in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Kura Oncology, Inc. earned -$0.77 per diluted share (EPS) in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
Kura Oncology, Inc. recorded an outflow of $63.2M in free cash flow in Q2 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Kura Oncology, Inc. held $70.2M in cash against $5.6M in long-term debt as of Q2 2026, with $118.2M of liabilities due within a year.
Not reported for Q2 2026.
Margins & Returns
Kura Oncology, Inc.'s gross margin was 98.8% in Q2 2026, indicating the percentage of revenue retained after direct costs. Against the prior quarter it is up 0.3 percentage points.
Kura Oncology, Inc.'s quarterly ROE was -141.1% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is down 119.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 73.1 percentage points.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Kura Oncology, Inc. invested $61.9M in research and development in Q2 2026. This represents a decrease of 1.4% from the same quarter a year earlier. Against the prior quarter it is down 5.2%.
Kura Oncology, Inc. invested $656K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 55.0% from the same quarter a year earlier. Against the prior quarter it is up 412.5%.
Not reported for Q2 2026.
KURA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $20.9M+36.5% | $18.3M+29.5% | $17.3M | $20.8M | $15.3M | $14.1M | N/A | N/A |
| Cost of Revenue | $243K | $262K | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $20.6M | $18.0M | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $61.9M-1.4% | $65.3M+16.6% | $64.4M | $67.9M+62.8% | $62.8M+58.0% | $56.0M+54.3% | N/A | $41.7M+42.2% |
| SG&A Expenses | $31.8M+26.1% | $31.6M+38.2% | $39.1M | $32.8M+80.6% | $25.2M+50.9% | $22.8M+25.6% | N/A | $18.2M+38.3% |
| Operating Income | -$73.0Mn/m | -$78.8Mn/m | -$86.3M | -$80.0Mn/m | -$72.7Mn/m | -$64.7Mn/m | N/A | -$59.9M |
| EBITDA | -$72.6Mn/m | -$78.5Mn/m | -$85.9M | -$79.8Mn/m | -$72.4Mn/m | -$64.5Mn/m | N/A | -$59.7M |
| Interest Expense | $345K-11.8% | $336K-12.0% | $346K | $393K-4.6% | $391K-3.7% | $382K-4.0% | N/A | $412K+2.0% |
| Income Tax | $5K | $8K-96.5% | N/A | N/A | N/A | $226K | N/A | N/A |
| Net Income | -$68.3Mn/m | -$73.3Mn/m | -$81.0M | -$74.1Mn/m | -$66.1Mn/m | -$57.4Mn/m | N/A | -$54.4Mn/m |
| EPS (Basic) | -$0.77n/m | -$0.83n/m | -$0.92n/m | -$0.85n/m | -$0.75n/m | -$0.66n/m | -$0.22n/m | -$0.63n/m |
| EPS (Diluted) | -$0.77n/m | -$0.83n/m | -$0.92n/m | -$0.85n/m | -$0.75n/m | -$0.66n/m | -$0.22n/m | -$0.63n/m |
| Diluted Shares (Avg) | 89M+1.4% | 89M+1.4% | N/A | 88M+0.8% | 88M+1.1% | 87M+4.2% | N/A | 87M+12.6% |
KURA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $587.8M-13.9% | $652.6M-12.3% | $738.4M-2.9% | $649.4M+35.6% | $682.4M+32.5% | $743.8M+34.3% | $760.2M+69.3% | $478.8M+1.1% |
| Current Assets | $559.4M-15.2% | $623.8M-13.9% | $708.7M-4.9% | $620.7M+34.0% | $660.1M+32.1% | $724.2M+34.7% | $744.8M+72.2% | $463.2M+0.7% |
| Cash & Equivalents | $70.2M-14.3% | $39.1M-23.8% | $149.1M-33.6% | $95.3M+92.6% | $81.9M+81.4% | $51.3M+23.5% | $224.5M+501.5% | $49.5M+72.2% |
| Short-Term Investments | $448.8M-18.2% | $541.7M-10.7% | $518.1M+3.0% | $454.4M+12.0% | $548.8M+23.0% | $606.9M+25.0% | $502.9M+30.1% | $405.8M-4.3% |
| Inventory | $2.5M | $843K | $413Kn/m | N/A | N/A | N/A | $0 | N/A |
| Accounts Receivable | $9.4M+106.5% | $9.3M-80.8% | $8.8M+327.4% | $35.9M | $4.6M | $48.7M | $2.1M | N/A |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $539.4M+43.1% | $544.7M+43.6% | $564.2M+62.8% | $406.8M+638.8% | $376.9M+668.5% | $379.4M+677.0% | $346.5M+570.7% | $55.1M+25.6% |
| Current Liabilities | $118.2M+10.3% | $101.5M+13.1% | $117.0M+48.6% | $121.3M+200.5% | $107.2M+220.4% | $89.8M+178.2% | $78.7M+123.2% | $40.4M+46.7% |
| Non-Current Liabilities | $421.2M+56.1% | $443.2M+53.0% | $447.3M+67.0% | $285.5M+1843.2% | $269.8M+1629.8% | $289.6M+1649.0% | $267.8M+1533.1% | $14.7M-9.9% |
| Long-Term Debt | $5.6M-14.4% | $9.7M+27.4% | $9.7M+40.4% | $5.3M-31.2% | $6.5M-24.1% | $7.7M-18.4% | $6.9M-25.9% | $7.8M-16.5% |
| Total Equity | $48.4M-84.1% | $107.9M-70.4% | $174.1M-57.9% | $242.5M-42.8% | $305.5M-34.5% | $364.4M-27.9% | $413.6M+4.1% | $423.8M-1.4% |
| Retained Earnings | -$1.3Bn/m | -$1.2Bn/m | -$1.2Bn/m | -$1.1Bn/m | -$1.0Bn/m | -$952.9Mn/m | -$895.4Mn/m | -$876.2Mn/m |
Not reported in any period shown, so not listed: Goodwill.
KURA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$62.5Mn/m | -$85.9Mn/m | $117.3M-56.4% | -$80.6Mn/m | -$28.8Mn/m | -$71.9Mn/m | $269.1Mn/m | -$43.4Mn/m |
| Depreciation & Amortization | $369K+64.7% | $355K+47.3% | $403K+97.5% | $164K-21.2% | $224K+10.9% | $241K+3.0% | $204K-4.7% | $208K-3.7% |
| Stock-Based Compensation | $8.2M+18.1% | $8.4M+7.3% | N/A | $11.0M+31.7% | $6.9M-17.6% | $7.8M-7.9% | N/A | $8.3M+17.4% |
| Capital Expenditures | $656K-55.0% | $128K-56.2% | $2.3M+523.9% | $2.6Mn/m | $1.5M+9012.5% | $292K+247.6% | $372K+2225.0% | $0-100.0% |
| Free Cash Flow | -$63.2Mn/m | -$86.0Mn/m | $115.0M-57.2% | -$83.2Mn/m | -$30.2Mn/m | -$72.2Mn/m | $268.8Mn/m | -$43.4Mn/m |
| Investing Cash Flow | $92.2M+56.4% | -$24.2Mn/m | -$64.6Mn/m | $94.0M+106.4% | $58.9M+36.5% | -$101.4Mn/m | -$95.0M-325.0% | $45.5M+432.0% |
| Financing Cash Flow | $1.5M+191.1% | $69K-51.7% | $1.1M+40.8% | $0-100.0% | $515K-83.1% | $143K-99.9% | $806K+16.6% | $2.2M+2521.4% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
KURA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 98.8% | 98.6% | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -349.8% | -431.5% | -497.6% | -385.5% | -475.3% | -458.6% | N/A | N/A |
| Net Margin | -327.3% | -401.5% | -467.2% | -357.2% | -432.5% | -407.1% | N/A | N/A |
| Return on Equity | -141.1%-119.4pp | -68.0%-52.2pp | -46.5% | -30.6%-17.7pp | -21.6%-10.7pp | -15.8%-5.9pp | N/A | -12.8%-3.9pp |
| Return on Assets | -11.6%-1.9pp | -11.2%-3.5pp | -11.0% | -11.4%0.0pp | -9.7%+0.2pp | -7.7%+1.2pp | N/A | -11.4%-3.2pp |
| Current Ratio | 4.73-1.4x | 6.15-1.9x | 6.06-3.4x | 5.12-6.4x | 6.16-8.8x | 8.07-8.6x | 9.46-2.8x | 11.47-5.2x |
| Debt-to-Equity | 0.12+0.1x | 0.09+0.1x | 0.060.0x | 0.020.0x | 0.020.0x | 0.020.0x | 0.020.0x | 0.020.0x |
| Liabilities-to-Equity | 11.14+9.9x | 5.05+4.0x | 3.24+2.4x | 1.68+1.5x | 1.23+1.1x | 1.04+0.9x | 0.84+0.7x | 0.130.0x |
| Asset Turnover | 0.040.0x | 0.030.0x | 0.02 | 0.03 | 0.02 | 0.02 | N/A | N/A |
| FCF Margin | -302.8% | -470.7% | 663.1% | -400.9% | -197.8% | -511.9% | N/A | N/A |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Kura Oncology, Inc. KURA | FY2025 | $67.5M | -$278.7M | N/A | $854.9M | 74/100 |
| ArriVent BioPharma, Inc. AVBP | FY2025 | N/A | -$166.3M | N/A | $1.0B | — |
| Tango Therapeutics, Inc. TNGX | FY2025 | $62.4M | -$101.6M | N/A | $3.9B | 66/100 |
| Sana Biotechnology, Inc. SANA | FY2025 | N/A | -$244.2M | N/A | $697.5M | — |
| Geron Corp GERN | FY2025 | N/A | -$83.5M | N/A | $719.6M | — |
Where Kura Oncology, Inc. Ranks
Frequently Asked Questions
What is Kura Oncology, Inc.'s annual revenue?
Kura Oncology, Inc. (KURA) reported $67.5M in total revenue for fiscal year 2025. This represents a 25.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Kura Oncology, Inc.'s revenue growing?
Kura Oncology, Inc. (KURA) revenue grew by 25.2% year-over-year, from $53.9M to $67.5M in fiscal year 2025.
Is Kura Oncology, Inc. profitable?
No, Kura Oncology, Inc. (KURA) reported a net loss of $296.8M over the trailing 12 months to June 30, 2026. In fiscal year 2025 it reported a net loss of $278.7M.
What is Kura Oncology, Inc.'s EBITDA?
Kura Oncology, Inc. (KURA) had EBITDA of -$302.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Kura Oncology, Inc. have?
As of fiscal year 2025, Kura Oncology, Inc. (KURA) had $149.1M in cash and equivalents against $9.7M in long-term debt.
What is Kura Oncology, Inc.'s return on equity (ROE)?
Kura Oncology, Inc. (KURA) has a return on equity of -160.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Kura Oncology, Inc.'s free cash flow?
Kura Oncology, Inc. (KURA) recorded an outflow of $70.7M in free cash flow during fiscal year 2025. This represents a -152.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Kura Oncology, Inc.'s operating cash flow?
Kura Oncology, Inc. (KURA) recorded an outflow of $64.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Kura Oncology, Inc.'s total assets?
Kura Oncology, Inc. (KURA) had $738.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Kura Oncology, Inc.'s capital expenditures?
Kura Oncology, Inc. (KURA) invested $6.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Kura Oncology, Inc. spend on research and development?
Kura Oncology, Inc. (KURA) invested $251.1M in research and development during fiscal year 2025.
What is Kura Oncology, Inc.'s current ratio?
Kura Oncology, Inc. (KURA) had a current ratio of 6.06 as of fiscal year 2025, which is generally considered healthy.
What is Kura Oncology, Inc.'s debt-to-equity ratio?
Kura Oncology, Inc. (KURA) had a debt-to-equity ratio of 0.06 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
What is Kura Oncology, Inc.'s liabilities-to-equity ratio?
Kura Oncology, Inc. (KURA) had a liabilities-to-equity ratio of 3.24 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
What is Kura Oncology, Inc.'s return on assets (ROA)?
Kura Oncology, Inc. (KURA) had a return on assets of -37.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Kura Oncology, Inc.'s P/E ratio?
Kura Oncology, Inc. (KURA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $854.9M as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Kura Oncology, Inc.'s price-to-sales ratio?
Kura Oncology, Inc. (KURA) trades at 11.1x sales, its market capitalization divided by $77.2M revenue, trailing 12 months to June 30, 2026. The market capitalization is $854.9M as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Kura Oncology, Inc.'s Altman Z-Score?
Kura Oncology, Inc. (KURA) has an Altman Z-Score of -1.62, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Kura Oncology, Inc.'s Piotroski F-Score?
Kura Oncology, Inc. (KURA) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Kura Oncology, Inc.'s earnings high quality?
Kura Oncology, Inc. (KURA) reported a net loss of $278.7M while operations used $64.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Kura Oncology, Inc. cover its interest payments?
Kura Oncology, Inc. (KURA) reported an operating loss of $303.6M against $1.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Kura Oncology, Inc.?
Kura Oncology, Inc. (KURA) scores 74 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.